Navigation Links
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Date:4/22/2008

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the Company's Board of Directors has decided against seeking stockholder approval for a reverse stock split at the Annual Meeting of Stockholders to be held on June 5, 2008. In light of recent gains in the Company's stock price, management's confidence in the Company's product candidate pipeline and the Company's current cash position, the Board of Directors concluded that it is not necessary to seek stockholder approval of a reverse stock split at this time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

On April 4, 2008, the Company issued a press release disclosing that it had received a Deficiency Notice from the Listing Qualifications Department of the NASDAQ Stock Market, LLC, and had announced its intention to seek stockholder approval for a reverse stock split. The Company remains committed to becoming compliant with all Nasdaq listing requirements.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation.

MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is t
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Receives Nasdaq Deficiency Notice
3. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
4. EntreMed Announces 2008 Corporate and Clinical Program Priorities
5. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
6. EntreMed to Present at BIO CEO and Investor Conference
7. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
8. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
9. EntreMed Appoints Senior Vice President of Research and Development
10. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... United States (PRWEB) September 16, 2014 ... Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies is ... This report focuses on the three principal types ... of research and development in cancer immunotherapy (which ... inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... very idea of fibers made of carbon nanotubes is neat, ... , The single-walled carbon nanotubes in new fibers created at ... a process designed by chemist Angel Mart and his colleagues. ... its results this month in the journal ACS Nano ... drawn together into a fiber. , Left to their own ...
(Date:9/15/2014)... DUBLIN , Sept. 15, 2014 Research ... "Whole Exome Sequencing Market by Product, by Services, by Technology, ... their offering. Whole Exome Sequencing (WES) is ... the genome, i.e. the exon. The exome, which is the ... of the total genome and is actually converted into proteins ...
(Date:9/15/2014)... , 15 de septiembre de 2014 La segunda ... a cabo del 12 al 18 de octubre. Como iniciativa ... y de sus compañías miembro s, la IPAW se ... mundial en torno a la colección de fuentes de plasma ... plasma al salvar y mejorar las vidas , Aumento ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3
... Md., Aug. 18, 2011 The Plasma Protein Therapeutics ... Medicaid Services (CMS) take necessary steps to improve drug ... At last week,s Advisory Panel on Ambulatory ... continued failure by CMS to remove hospitals that purchase ...
... Aug. 18, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0588171/Global-Genetic-Testing-Market-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics In a ... represents a highly attractive segment. Genetic testing ...
... 2011 Poplar Healthcare, a leading laboratory services company, ... the existing entities known as GI Pathology, D-PATH Dermatopathology ... expand," remarks William McDowell, CEO of Poplar Healthcare, "we ... brand to which our individual companies could belong, while ...
Cached Biology Technology:PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 2PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 3PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 4Global Genetic Testing Market Analysis 2Global Genetic Testing Market Analysis 3Poplar Healthcare Forms Parent Company, Launches New Web Site 2
(Date:9/15/2014)... as much as 170 tons, the blue whale is the ... living thing ever seen on Earth. So there,s no way ... larvae, which measure millimeters in length and tip the scales ... so fast, says L. Mahadevan, the Lola England de Valpine ... of Physics. , Using simple hydrodynamics, a team of ...
(Date:9/15/2014)... tip the balance between ridding the body of a ... a report appearing in The Journal of ... viruses cause chronic infections in roughly three-quarters of infected ... diseases including cirrhosis and cancer. A few patients successfully ... CD8 + T cells. The protective effects of ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  GENiSYSS, ... California , announces the public launch of ... very unique, patented product, combining room temperature, long-term ... the only company to make personal storage of ... Photo - http://photos.prnewswire.com/prnh/20140912/145664   Photo - ...
Breaking Biology News(10 mins):The science behind swimming 2The science behind swimming 3GENiSYSS Launches Website about Easy, Inexpensive Home DNA Storage for Everyone 2
... Ribbons of ultrathin graphene combined with polyurethane paint meant for ... according to scientists at Rice University. The Rice ... developed the compound to protect marine and airborne radars with ... The research was published this week in the ...
... causes diseases like Alzheimer,s, Parkinson,s and Creutzfeldt-Jakob disease. ... lead to the development of new composite materials ... tomorrow, and even make objects invisible. Researchers ... unexpected discovery about amyloid in an article published ...
... 2013Time-lapse movies of a cellular heaven and hell, a crane ... of muscle cells were recognized with the top three awards ... Cell Biology Video Contest for 2013. The awards were ... ASCB Annual Meeting, Sunday , Dec. 14, in New Orleans. ...
Cached Biology News:Graphene nanoribbons an ice-melting coat for radar 2Graphene nanoribbons an ice-melting coat for radar 3Alzheimer substance may be the nanomaterial of tomorrow 2Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 2Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 3
...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Biology Products: